NO973685L - Multi-tumor avvikende vekstgener - Google Patents

Multi-tumor avvikende vekstgener

Info

Publication number
NO973685L
NO973685L NO973685A NO973685A NO973685L NO 973685 L NO973685 L NO 973685L NO 973685 A NO973685 A NO 973685A NO 973685 A NO973685 A NO 973685A NO 973685 L NO973685 L NO 973685L
Authority
NO
Norway
Prior art keywords
genes
aberrant growth
growth genes
tumor aberrant
tumor
Prior art date
Application number
NO973685A
Other languages
English (en)
Norwegian (no)
Other versions
NO973685D0 (no
Inventor
Joern Bullderdiek
Willem Jan Marie Van De Ven
Henricus Franscis Schoenmakers
Rafael Mols
Original Assignee
Leuven Res & Dev Vzw
Joern Bullderdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973685(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leuven Res & Dev Vzw, Joern Bullderdiek filed Critical Leuven Res & Dev Vzw
Publication of NO973685D0 publication Critical patent/NO973685D0/no
Publication of NO973685L publication Critical patent/NO973685L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
NO973685A 1995-02-17 1997-08-11 Multi-tumor avvikende vekstgener NO973685L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95200390 1995-02-17
EP95201951A EP0727487A1 (de) 1995-02-17 1995-07-14 Multi-Tumor abweichende Wachstumsgene
PCT/EP1996/000716 WO1996025493A1 (en) 1995-02-17 1996-02-19 Multiple-tumor aberrant growth genes

Publications (2)

Publication Number Publication Date
NO973685D0 NO973685D0 (no) 1997-08-11
NO973685L true NO973685L (no) 1997-10-17

Family

ID=8220025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973685A NO973685L (no) 1995-02-17 1997-08-11 Multi-tumor avvikende vekstgener

Country Status (14)

Country Link
US (3) US6544784B1 (de)
EP (3) EP0727487A1 (de)
JP (4) JPH11500614A (de)
KR (1) KR19980702276A (de)
AT (1) ATE338114T1 (de)
AU (1) AU4879096A (de)
CA (1) CA2213237A1 (de)
CZ (1) CZ247597A3 (de)
DE (2) DE69636495T2 (de)
FI (1) FI973354A7 (de)
HU (1) HUP9800028A3 (de)
NO (1) NO973685L (de)
PL (1) PL321831A1 (de)
WO (1) WO1996025493A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6323329B1 (en) 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
CA2259635A1 (en) * 1997-05-07 1998-11-12 Kiran Chada Hmgi proteins in tumors and obesity
EP0878552A1 (de) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1078098A1 (de) 1998-05-04 2001-02-28 Dako A/S Verfahren und sonden zur detektion chromosomaler aberrationen
US6601371B1 (en) 1998-05-05 2003-08-05 Erwin Fertig Packaging machine
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE19904514A1 (de) * 1999-02-04 2000-08-10 Joern Bullerdiek Mittel zur Prävention und/oder Behandlung von Leiomyomen
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20050008643A1 (en) * 2001-06-27 2005-01-13 Ora Bernard Diagnostic methods and agents
ATE395602T1 (de) * 2001-12-19 2008-05-15 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
WO2003087317A2 (en) * 2002-04-05 2003-10-23 Cyternex, Inc. Methods for targeting quadruplex dna
US20030219742A1 (en) * 2002-03-29 2003-11-27 Sanjay Bhanot Antisense modulation of HMGI-C expression
AU2003262778A1 (en) * 2002-08-20 2004-03-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for regulating transcription by targeting quadruplex dna
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
JP2008520552A (ja) 2004-10-22 2008-06-19 メディミューン,インコーポレーテッド Hmgb1に対する高親和性の抗体およびその使用法
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
JP5366039B2 (ja) * 2008-03-18 2013-12-11 株式会社常光 悪性腫瘍の予想、診断のための方法および組成物
US20100297649A1 (en) * 2009-04-22 2010-11-25 Oliveira Andre M Methods and materials for detecting gene amplification
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
US20180127831A1 (en) * 2015-05-21 2018-05-10 Université de Montréal Prognostic markers of acute myeloid leukemia survival

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
DE69033772T2 (de) * 1989-11-02 2002-06-20 Dictytech Pty Ltd., Frenchs Forest Verbesserte plasmidvektoren für zelluläre schleimpilze der gattung dictyostelium
US5756307A (en) * 1991-09-20 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Sequence of human dopamine transporter cDNA
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer

Also Published As

Publication number Publication date
PL321831A1 (en) 1997-12-22
FI973354L (fi) 1997-10-16
JP2007082549A (ja) 2007-04-05
US20030190285A1 (en) 2003-10-09
EP1762619B1 (de) 2013-06-26
EP1762619A2 (de) 2007-03-14
CZ247597A3 (cs) 1998-07-15
EP0811061B2 (de) 2010-07-21
JP2009254378A (ja) 2009-11-05
US6544784B1 (en) 2003-04-08
AU4879096A (en) 1996-09-04
FI973354A7 (fi) 1997-10-16
JPH11500614A (ja) 1999-01-19
HUP9800028A2 (hu) 1998-04-28
EP0811061A1 (de) 1997-12-10
ATE338114T1 (de) 2006-09-15
US20110318834A1 (en) 2011-12-29
FI973354A0 (fi) 1997-08-15
KR19980702276A (ko) 1998-07-15
EP0811061B1 (de) 2006-08-30
DE69636495T2 (de) 2007-05-24
HUP9800028A3 (en) 2001-02-28
NO973685D0 (no) 1997-08-11
CA2213237A1 (en) 1996-08-22
EP0727487A1 (de) 1996-08-21
DE69636495D1 (de) 2006-10-12
DE811061T1 (de) 2002-10-17
WO1996025493A1 (en) 1996-08-22
EP1762619A3 (de) 2007-05-09
JP2008099698A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
NZ316787A (en) Methods and compositions for the selective modification of nucleic acids
AU7489687A (en) Translation of mrna
NO872757L (no) Alkynylaminonukleotider og fremgangsmŸte for fremstilling av disse.
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
ATE366806T1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
FR2637612B1 (fr) Sequences de nucleotides codant pour une proteine a activite ureasique
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
DE69636495D1 (de) Multi-tumor abweichende wachstumsgene
EP1170992A4 (de) Gereinigte und isolierte gene der -i(piwi)-familie, ihre genprodukte; und verfahren zu ihrer verwendung
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
MXPA03006984A (es) Secuencia de nucleotidos que median la fertilidad masculina y metodo de uso de la misma.
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE69816467D1 (de) Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
HUP9802681A1 (hu) Onkogénnel vagy vírussal szabályozott expressziós rendszerek
MX9806041A (es) Proteina purificada sr-p70.
DE69332375D1 (de) Hundecoronavirus s gen und verwendung davon
AU6144294A (en) Plant virus resistance conferring polyribozyme and resistant plants producing same
RU93031156A (ru) Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин
DK0688786T3 (da) Hydrazino- og hydroxyamino-14beta-hydroxyandrostanderivater med aktivitet på det cardiovaskulære system, fremgangsmåder til deres fremstilling og farmaceutiske præparater indeholdende disse.
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application